The P-glycoprotein transport system and cardiovascular drugs.
about
Update on Edoxaban for the Prevention and Treatment of Thromboembolism: Clinical Applications Based on Current EvidenceGuidance for the practical management of the direct oral anticoagulants (DOACs) in VTE treatmentClinical Implications of P-Glycoprotein Modulation in Drug-Drug Interactions.Towards a rational design of solid drug nanoparticles with optimised pharmacological properties.Use and outcomes of antiarrhythmic therapy in patients with atrial fibrillation receiving oral anticoagulation: results from the ROCKET AF trial.A multifunctional lipid nanoparticle for co-delivery of paclitaxel and curcumin for targeted delivery and enhanced cytotoxicity in multidrug resistant breast cancer cells.Drug-drug interaction studies of cardiovascular drugs involving P-glycoprotein, an efflux transporter, on the pharmacokinetics of edoxaban, an oral factor Xa inhibitor.A pharmacogenetic pilot study reveals MTHFR, DRD3, and MDR1 polymorphisms as biomarker candidates for slow atorvastatin metabolizers.A physiologically based pharmacokinetic drug-disease model to predict carvedilol exposure in adult and paediatric heart failure patients by incorporating pathophysiological changes in hepatic and renal blood flowsEfficacy and Safety of Direct Acting Antivirals in Kidney Transplant Recipients with Chronic Hepatitis C Virus InfectionNovel understanding of ABC transporters ABCB1/MDR/P-glycoprotein, ABCC2/MRP2, and ABCG2/BCRP in colorectal pathophysiologyClassification of P-glycoprotein-interacting compounds using machine learning methods.Genetic and Nongenetic Factors Affecting Clopidogrel Response in the Egyptian Population.Unravelling the complex drug-drug interactions of the cardiovascular drugs, verapamil and digoxin, with P-glycoprotein.P-glycoprotein transporter in drug development.The Effects of Cetirizine on P-glycoprotein Expression and Function In vitro and In situSimple and rapid assay for effect of the new oral anticoagulant (NOAC) rivaroxaban: preliminary results support further tests with all NOACsLobular Distribution and Variability in Hepatic ATP Binding Cassette Protein B1 (ABCB1, P-gp): Ontogenetic Differences and Potential for Toxicity.Current and new oral antithrombotics in non-valvular atrial fibrillation: a network meta-analysis of 79 808 patients.Digoxin-specific antibody fragments in the treatment of digoxin toxicity.Relevance of P-glycoprotein in stroke prevention with dabigatran, rivaroxaban, and apixaban.Research progress on the multidrug resistance mechanisms of osteosarcoma chemotherapy and reversal.Dual antiviral therapy for HIV and hepatitis C - drug interactions and side effects.In vitro and in vivo effects of morin on the intestinal absorption and pharmacokinetics of olmesartan medoxomil solid dispersions.Intestinal permeability and P-glycoprotein-mediated efflux transport of ticagrelor in Caco-2 monolayer cells.Role of Digoxin in Atrial Fibrillation.Drug-drug interactions of non-vitamin K oral anticoagulants.Transporter effects on cell permeability in drug delivery.Loperamide-Related Deaths in North Carolina.Teaching an Old Dog New Tricks: Colchicine in Cardiovascular Medicine.Cellular Models and In Vitro Assays for the Screening of modulators of P-gp, MRP1 and BCRP.Effect of risperidone metabolism and P-glycoprotein gene polymorphism on QT interval in patients with schizophrenia.Clinical Pharmacokinetics of Sacubitril/Valsartan (LCZ696): A Novel Angiotensin Receptor-Neprilysin Inhibitor.Drug interactions in HIV-infected patients treated for hepatitis C.Safety, clinical effectiveness and trough plasma concentrations of intravenous posaconazole in patients with haematological malignancies and/or undergoing allogeneic haematopoietic stem cell transplantation: off-trial experience.Ciprofloxacin and statin interaction: a cautionary tale of rhabdomyolysis.Age-dependent redox status in the brain stem of NO-deficient hypertensive rats.Pravastatin-Induced Eczematous Eruption Mimicking Psoriasis.Inhibitory effect of clemastine on P-glycoprotein expression and function: an in vitro and in situ studyCooperativity between verapamil and ATP bound to the efflux transporter P-glycoprotein.
P2860
Q26782483-FADBF3CC-F9D5-45C5-AEB7-1B7B04BD86C9Q28076077-285532D7-7A7A-41E5-961F-75CACBDE9FE6Q30234940-858EA03A-9D07-4328-8360-1A277C8E71ABQ30372133-4C7F2014-3A46-4F48-AB09-E7012DFACA79Q33671190-4DCD05F1-0320-4681-8680-7155B46DCB0FQ33728332-FB097B93-998D-485C-9C1D-CD10B9D4C60FQ34653407-CCB3E326-05CE-4ACF-8127-CF7F2CE4BD2BQ35917726-7ED8B287-6F39-477E-8246-4D34896ED7AAQ36025902-F0A4224A-B5F6-47F3-9DCF-F37273579B9CQ36077546-B05245C9-AF63-4EFD-9C1D-EFAAC91BFA26Q36245600-A42AD61E-F3E8-4EF6-A365-C47D2BE79350Q36550636-7731F11C-1FB0-4BD3-83C4-E23D73BA7408Q36599251-25B7638F-2052-4CC4-85C8-6C1A3CC40809Q36691249-DF267FF8-528A-4B83-A7FB-BFA9DB4AF640Q36755799-64F4CD6F-8426-4D70-848A-89C8E0742238Q36837150-BC0E5EB5-1887-4772-B4CB-2EC1D4D26939Q37681956-5196D9CD-E088-4EC6-96BA-CF220C1E3ECDQ37731228-F50AB8D8-5CB9-4D08-8A91-A1413725CFADQ38134680-32873407-10B6-42E3-AC91-2FBC1879706EQ38236647-2FE38CC9-C318-4A61-8091-E1ABF5BE0A35Q38330349-21311D50-E9A4-43AE-BB12-B7DCB0EBFC25Q38349935-4C4159EC-544D-4596-B8E1-0715744E24B7Q38554604-04E6DA1E-502C-4821-B138-35DD59ACFC81Q38754044-88E2987C-BB8F-44D2-8948-E8F095B1910EQ38758204-AC0923B2-571B-4DD3-B366-E98F020DCCD2Q38805268-8E304851-9A1B-44A0-8415-388E5A27D1F0Q38830358-90F64F42-7DE8-4055-A304-44391BEFAB9DQ38905979-4581ECC8-A9D1-463A-A4C1-B5CA2A6463F2Q38913158-9837B506-2FAB-4CD7-983C-CE451641F258Q39206224-125359CB-84EB-4125-8BBF-69EBAAE72500Q39233839-D6DC97C5-04F1-411B-B830-72FE8032E9B4Q39240358-859ECC39-66E6-49D6-9CBA-34EB6BA7C99CQ39247505-31B8F0B4-D291-4EBF-B247-3927733EB2D7Q40143109-67554D25-D0DE-458F-95BE-5866F7EEF76BQ40577292-4850AED1-86D4-463B-B505-94BB3EBB2C79Q40596214-2459A707-CD6F-4D4E-AD19-29A7917DA348Q41274362-AAFBA946-F5CD-4707-8DC6-8CF63111BD03Q41376230-C2C3E496-0D05-489F-8B26-9EAEDEE7F9B2Q41887937-337CF1F1-DCA0-48D2-AA47-BAC9607A9A00Q42284764-040EE00F-D231-42AF-B6A9-C889D4B1F5F3
P2860
The P-glycoprotein transport system and cardiovascular drugs.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
The P-glycoprotein transport system and cardiovascular drugs.
@en
type
label
The P-glycoprotein transport system and cardiovascular drugs.
@en
prefLabel
The P-glycoprotein transport system and cardiovascular drugs.
@en
P2093
P1476
The P-glycoprotein transport system and cardiovascular drugs
@en
P2093
Jeanne Mendell
Jeffrey D Wessler
Laura T Grip
P304
P356
10.1016/J.JACC.2013.02.058
P407
P577
2013-04-03T00:00:00Z